Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2018 Dec 6;18(3):706–717. doi: 10.1158/1535-7163.MCT-18-0395

Figure 6.

Figure 6.

In vivo BRAFi therapy triggered reversible MPC subpopulation changes. (A) Subcutaneously grafted YUMM1.7 tumors in C57BL/6J mice exhibited a sensitive drug response to BRAFi chow (n=4 to 6 per treatment condition). Arrows indicated that BRAFi chow was provided to mice in the treatment group on day 25 and removed on day 33. BRAFi-treated tumors were harvested on day 33 and BRAFi-removed tumors were harvested on day 42. (B) Kdm5b mRNA level increased in BRAFi treated-tumors and was reduced closer to the untreated tumors nine days after treatment removal (****, p≤0.0001). (C) The percentage of CD34− tumor cells increased after eight days of BRAFi chow treatment (*, p≤0.05; **, p≤0.01; ****, p≤0.0001). Shown are flow cytometry plots (left) and quantification of flow cytometry analysis (right). Flow cytometry analysis gated only live, non-immune cells with negative propidium iodide and CD45 staining.